Dr Reddy’s Laboratories has dropped plans of developing a generic version of Novartis’ anti-fungal skin/nails treatment drug Lamifil (terbinafine hydrochloride), which has estimated sales of $1 billion in its various variants. The company is believed to have spent about Rs 25 crore on the development process so far, but with the drug indicating low levels of efficacy, it has been dumped, said sources familiar with the development.
C.0